1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Global Antibody Drug Conjugates  Market – Analysis By Drugs , Pipeline Drugs, Regulations: Opportunities and Forecasts  - By Region ; By Country

Global Antibody Drug Conjugates Market – Analysis By Drugs , Pipeline Drugs, Regulations: Opportunities and Forecasts - By Region ; By Country

  • March 2017
  • 154 pages
  • ID: 4807875

Summary

Table of Contents

Search Inside

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Antibody Drug Conjugates Market on the basis of Analysis By Drug (Adcetris, Kadcyla), Pipeline Analysis (Developer, Phase, Indication, Status, Cytotoxic Payload, Linker, Target), By Region (North America, Europe, APAC and ROW) and By Country (U.S., Canada, U.K., Germany, France, China, India, Japan, Singapore, Brazil and South Africa).

Over the recent years, the global antibody drug conjugates industry has been growing rapidly as the global sales of Adcetris and Kadcyla have been witnessing rapid growth after their approval. Globally, the growth in the antibody drug conjugates market is driven by large number of ADC drugs in pipeline, rise in global incidences of cancer and wider therapeutic window offered by ADCs.

According to Azoth Analytics research report, “Global Antibody Drug Conjugates (ADC) Market – Analysis By Drugs (Adcetris, Kadcyla), Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022)”, global market is projected to display a robust growth represented by a CAGR of 21.82% during 2017 – 2022, chiefly driven by large number of ADC drugs in pipeline, rising number of cancer patients and wider therapeutic window offered by antibody drug conjugates.

Among the drugs, Kadcyla currently dominates the antibody drug conjugates market but will be surpassed by Adcetris in forecasted period. Among the regions, North America is predicted to advance at the highest rate, mainly driven by increase in several ADC molecules expected to gain FDA approval in next few years

The report titled, “Global Antibody Drug Conjugates (ADC) Market – Analysis By Drugs (Adcetris, Kadcyla), Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022)”, has covered and analysed the potential of Global Antibody Drug Conjugates Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global food service equipment market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)
- Antibody Drug Conjugates Market (ADC) Market
- Adcetris Market
- Kadcyla Market
- ADC Pipeline - By Developer, Phase, Indication and Status
- ADC Pipeline - By Cytotoxic Payload, Linker and Target

Regional Markets – N. America, Europe, APAC, RoW (Actual Period: 2012-2016, Forecast Period: 2017-2022)
- Antibody Drug Conjugates Market (ADC) Market
- Adcetris Market
- Kadcyla Market
- ADC Pipeline - By Developer, Phase, Indication and Status
- ADC Pipeline - By Cytotoxic Payload, Linker and Target

Country Analysis - US, Canada, UK, Germany, France, Japan, China, Singapore, India, Brazil, South Africa (Actual Period: 2012-2016, Forecast Period: 2017-2022)
- Antibody Drug Conjugates Market (ADC) Market

Other Report Highlights:
- Market Dynamics – Trends, Drivers, Challenges
- Porter’s Five Forces Analysis
- SWOT Analysis
- Policy and Regulation
- Company Analysis - Hoffmann-La Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc, Pfizer Inc., Sanofi, AbbVie Inc, Cellldex Therapeutics, Synthon, Progenics Pharmaceuticals

Customization of the Report
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Veronica helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Breast Cancer - First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline Diversification for Late-Stage Breast Cancer

Frontier Pharma: Breast Cancer - First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline Diversification for Late-Stage Breast Cancer

  • $ 6995
  • Industry report
  • July 2018
  • by GBI Research

Frontier Pharma: Breast Cancer - First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline Diversification for Late-Stage Breast CancerSummaryBreast cancer remains a major global healthcare ...

Digital Landscape: Breast Cancer

Digital Landscape: Breast Cancer

  • $ 6000
  • Industry report
  • September 2018
  • by GlobalData

Digital Landscape: Breast CancerSummary"Digital Landscape: Breast Cancer", analyzes digital activities undertaken by pharma in support of therapies for Breast Cancer.- The report includes digital activities ...

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

  • $ 4995
  • Industry report
  • July 2018
  • by GBI Research

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the MarketSummaryMany countries are facing the challenge of an aging ...

Global Alpha Emitters Market $ 4250 August 2018


ref:plp2017

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on